Sarissa Consulting’s Intersect ENT, Inc XENT Stock Holding History

Sarissa Consulting’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-89,745	Closed	-$2.51M	–	65
2022 Q1	$2.51M	Buy	89,745 +66,648	+289%	+$1.83M	3.98%	11
2021 Q4	$631K	Buy	+23,097	New	+$626K	0.81%	31

Sarissa Consulting's XENT Position: Q2 2022 in Review

Sarissa Consulting sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 89,745 shares — an estimated $2.51M sold.

Sarissa Consulting first reported a position in XENT in Q4 2021 and held it in 2 quarters. The position peaked at $2.51M in Q1 2022. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.

Sarissa Consulting reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
Sarissa Consulting sold 89,745 Intersect ENT, Inc shares in Q2 2022, an estimated $2.51M.
Sarissa Consulting first reported a position in Intersect ENT, Inc in Q4 2021 and held it in 2 quarters.
Sarissa Consulting's Intersect ENT, Inc position peaked at $2.51M in Q1 2022.
0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.

Based on Sarissa Consulting's 13F filing for Q2 2022, filed 15 Aug 2022.